Tempus AI, Inc. announced that eight abstracts of its genomic and clinical AI research have been accepted for presentation at the 2026 ASCO® Gastrointestinal Cancers Symposium, scheduled for January 8–10 in San Francisco. The submissions span multiple GI tumor types, including colorectal, pancreatic and hepatobiliary cancers, and showcase the company’s AI-driven biomarker discovery platform. Three abstracts detail novel predictive models for treatment response in microsatellite instability–high colorectal cancer, while two focus on integrating radiomics and genomics to improve early detection of pancreatic adenocarcinoma. The remaining presentations address immune microenvironment profiling in hepatocellular carcinoma and a real-world outcomes analysis for advanced gastric cancer patients treated with emerging immunotherapies. These findings reflect Tempus’s commitment to accelerating precision oncology research and underscore its growing role in GI cancer diagnostics and therapeutic decision support.

In its Q3 2025 financial report, Tempus AI reported a cash position of $760 million and maintained zero current debt on its balance sheet, positioning the company with substantial financial flexibility to fund ongoing R&D initiatives and potential strategic collaborations. The company also achieved positive adjusted EBITDA for the quarter, driven by increased commercial adoption of its sequencing and AI analytics services in both clinical and research markets. Operating expenses rose modestly as investment in data infrastructure and headcount expansion continued, but gross margin improvements of 4 percentage points year-over-year indicate economies of scale are taking hold. Analysts note that this strong solvency profile reduces refinancing risk and provides Tempus with ample runway to execute its precision medicine roadmap through 2026.